OS was significantly better in ER expressed vs. ER negative and in PgR exhibited vs PgR negative lung adenocarcinoma patients (median survival=45 months vs. 19 months in both groups, HR=0.38 [95% confidence interval (CI)=0.16-0.93], p=0.03 and HR=0.42 [95% CI=0.15-0.92], p= 0.04, respectively). This evidence concerns the gene ESR1 and lung adenocarcinoma.